Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab in Patients with Squamous Cell Cancer of the Head and Neck
CAMBRIDGE - Infinity Pharmaceuticals, Inc. , a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced...
Source: marketscreener.com